Biotech Values

[DewDiligence]

FREQ reverse-merges with—(private)—Korro Bio:

https://finance.yahoo.com/news/korro-bio-frequency-therapeutics-announce-103000131.html

Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to operate under Korro Bio, Inc. and will apply to trade on Nasdaq under the ticker symbol "KRRO".

… Pre-merger Frequency Therapeutics stockholders are expected to own approximately 8% of the combined company and pre-merger Korro Bio stockholders (including those purchasing Korro Bio shares in the private financing discussed above) are expected to own approximately 92% of the combined company.

FREQ has essentially been a shell since its second failure in hearing loss in Feb 2023 (#msg-171194013).